Design Therapeutics, Inc.
NASDAQ: DSGN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Pratik Shah
- Employees
- 56
- Headquarters
- Carlsbad, United States
- IPO year
- 2021
- Market cap
- $860.7M
- Website
- https://www.designtx.com
Loading DSGN…
Loading profile data…Frequently asked questions about DSGN
What does Design Therapeutics, Inc. (DSGN) do?
Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial funct...
Where does DSGN trade?
Design Therapeutics, Inc. (DSGN) trades on the NASDAQ Global Select.
What sector is DSGN in?
Design Therapeutics, Inc. (DSGN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Design Therapeutics, Inc.?
Pratik Shah is the chief executive officer of Design Therapeutics, Inc. (DSGN).
Where is Design Therapeutics, Inc. headquartered?
Design Therapeutics, Inc. is headquartered in United States.
Does DSGN pay a dividend?
Design Therapeutics, Inc. (DSGN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did DSGN go public?
Design Therapeutics, Inc. (DSGN) completed its initial public offering in 2021.